### Clinical Trial Award

**Go to:**
- Program Announcement
- General Application Instructions

**Grants.gov Funding Opportunity Number:**
HT942524PRMRPCTA

<table>
<thead>
<tr>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Assistant Professor level or above (or equivalent) | • Preproposal submission is required; application submission is by invitation only.  
• Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition in the Topic Area(s) of interest.  
• Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.  
• Two options will be offered:  
  o **Planning Phase with Clinical Trial Option:** Provides support to prepare and submit an Investigational New Drug/Investigational Device Exemption (IND/IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded.  
  o **Clinical Trial Only Option:** Provides support for the clinical trial. IND or IDE applications to the FDA, if needed, must be approved by the FDA and included in the application submission. | **Clinical Trial:**  
• A funding limit is not defined; requested funding must be appropriate for the scope of work proposed.  
• The maximum period of performance for the clinical trial is 4 years. | **Pre-Application (Preproposal):**  
May 13, 2024  
5:00 p.m. Eastern time |
| | | **Application:**  
August 19, 2024  
11:59 p.m. Eastern time |

### Discovery Award

**Go to:**
- Program Announcement
- General Application Instructions

**Grants.gov Funding Opportunity Number:**
HT942524PRMRPDA

<table>
<thead>
<tr>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Postdoctoral fellow or clinical fellow (or equivalent) and above | • Supports innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies or applications.  
• Not intended to support the logical progression of an already established line of questioning.  
• **Clinical trials will not be funded.** | • The maximum allowable funding for the entire period of performance is **$275,000** for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 2 years. | **Pre-Application (Letter of Intent):**  
May 6, 2024  
5:00 p.m. Eastern time |
| | | **Application:**  
May 23, 2024  
11:59 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Investigator-Initiated Research Award | Assistant Professor level or above (or equivalent)                            | • Supports research that will make an important contribution toward research, patient care and/or quality of life for a disease of condition in the Topic Area(s) of interest.  
• Clinical trials will not be funded. | • The maximum allowable funding for the entire period of performance is **$1.0 million** for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 4 years. | Pre-Application (Letter of Intent):  
May 6, 2024  
5:00 p.m. Eastern time  
Application:  
May 23, 2024  
11:59 p.m. Eastern time |

| Impact Award                        | Assistant Professor level or above (or equivalent)                            | • Supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from real-world environment to foster clinical applicability in the Topic Area(s) of interest.  
• Partnering Principal Investigator Option available.  
• Clinical trials will not be funded. | • The maximum allowable funding for the entire period of performance is **$2.0 million** for direct costs for single investigators and **$2.6 million** for partnering investigators.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 4 years. | Pre-Application (Letter of Intent):  
May 13, 2024  
5:00 p.m. Eastern time  
Application:  
June 6, 2024  
11:59 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Lifestyle and Behavioral Health Interventions Research Award | Assistant Professor level or above (or equivalent) | • Supports using a combination of scientific disciplines including behavioral health, psychology, psychometrics, biostatistics and epidemiology, surveillance and public health that will enhance patient experience and improve outcomes.  
  • Projects may include clinical research or clinical trials for **interventions that do not require regulation by the FDA.**  
  • Encourages patient advocate participation in the research team.  
  • **Animal studies will not be funded.** | • The maximum allowable funding for the entire period of performance is **$3.0 million** for direct costs.  
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
  • The maximum period of performance is **4 years.** | Pre-Application  
  (Letter of Intent):  
  May 13, 2024  
  5:00 p.m. Eastern time  
  Application:  
  June 6, 2024  
  11:59 p.m. Eastern time |
| Technology/Therapeutic Development Award            | Assistant Professor level or above (or equivalent) | • Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life.  
  • Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.  
  • **Clinical trials will not be funded.** | • The maximum allowable funding for the entire period of performance is **$4.0 million** for direct costs.  
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
  • The maximum period of performance is **4 years.** | Pre-Application  
  (Letter of Intent):  
  May 13, 2024  
  5:00 p.m. Eastern time  
  Application:  
  June 6, 2024  
  11:59 p.m. Eastern time |